Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)
08:53am, Saturday, 17'th Jan 2026
All three of these companies are well established, with solid growth prospects. Each faces some struggles, but all are paying shareholders to wait for stronger results.
Pfizer: Rebound Has Just Started
01:08pm, Friday, 16'th Jan 2026
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial sta
Pfizer: The Most Intriguing Value Play Of 2026
08:58am, Thursday, 15'th Jan 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keyt
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
06:46pm, Wednesday, 14'th Jan 2026
In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
08:45am, Wednesday, 14'th Jan 2026
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.
Inside Pfizer's Oncology Performance Ahead of Q4 Results
08:55am, Tuesday, 13'th Jan 2026
PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.
First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals
07:38am, Tuesday, 13'th Jan 2026
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy
06:11am, Tuesday, 13'th Jan 2026
Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in COVI
Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
02:14am, Tuesday, 13'th Jan 2026
Pfizer Inc. (NYSE: PFE - Get Free Report) has been given an average recommendation of "Hold" by the twenty brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
06:43pm, Monday, 12'th Jan 2026
Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:16pm, Monday, 12'th Jan 2026
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus Shares Jump After Strong Preliminary 2025 Results
01:35pm, Monday, 12'th Jan 2026
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
Bristlecone Advisors LLC Has $1.26 Million Stock Holdings in Pfizer Inc. $PFE
04:00am, Monday, 12'th Jan 2026
Bristlecone Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE: PFE) by 34.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange C
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in
